Icagen veranstaltet heute eine Call Conference zu den Zahlen des letzten Quartals - 500 Beiträge pro Seite

[dottore]

gerade gestern wurde bekannt wie folgt:

View printer-friendly version
<< Back
Icagen Announces Lifting of Partial Clinical Hold of ICA-105665
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today that the FDA has lifted the partial clinical hold related to the development of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist, for the treatment of epilepsy. Accordingly, the Company is planning to initiate a proof-of-concept study in patients with photosensitive epilepsy.

The photosensitive epilepsy study was designed with international experts including members of the Epilepsy Study Consortium and will be conducted at multiple clinical research centers in the U.S. Eligible subjects are those patients with demonstrated epileptiform activity by electroencephalogram (EEG) in response to photic stimulation (also called a "photoparoxysmal response to light") and represent a small subset of all patients with epilepsy. In accordance with a standardized protocol, patients receive single doses of placebo or ICA-105665 on successive days followed by photic stimulation with EEG monitoring. The study measures the ability of ICA-105665 to reduce the photic-induced epileptiform EEG responses. The duration of an observed effect will also be measured over time. A range of doses of ICA-105665 will be studied in successive cohorts, and the response observed in each cohort will determine the subsequent dose for the next cohort. The objective of the study is to determine a potential dose range to study in subsequent, more advanced clinical trials. The study is anticipated to be completed by mid-2010 but interim results may be available earlier.

In addition, the Company continues preparations for a proof-of-concept pain study, which is also expected to be initiated during the third quarter. This study will be conducted at a single clinical research site in the United Kingdom. The pain trial involves the study of healthy volunteers exposed to mildly painful stimuli under controlled conditions. The study will employ a triple cross-over design comparing the ability of ICA-105665, ibuprofen and placebo to decrease the sensation of pain in response both to the injection of a small amount of capsaicin under the skin and to a simulated sunburn. Initial results from this study are expected by early 2010.

"We are pleased to be able to proceed with the development of ICA-105665 in patients with epilepsy," noted Seth V. Hetherington, M.D., SVP of Clinical Development and Regulatory Affairs of Icagen. "This compound is a highly selective agonist of KCNQ channel subtypes, and has demonstrated excellent activity in a broad range of preclinical epilepsy models. Additionally, in a single dose Phase I study as well as a multi-dose Phase I study comprised of both healthy volunteers and patients with epilepsy, ICA-105665 has been well tolerated at doses ranging from 30 to 400mg per day, the highest dose tested. We look forward to conducting both the photosensitive epilepsy trial and the pain trial with the goal of establishing proof-of-concept for this novel compound in epilepsy and pain."

About Icagen

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. The Company has clinical stage programs in epilepsy and asthma.

Das nenne ich timing! An diesem Wert werde ich mich noch lange freuen ....

[dottore]

Antwort auf Beitrag Nr.: 37.706.418 von dottore am 04.08.09 13:03:45

"noch lange freuen"?
Erstmal gings 20% in den Keller. Und da sind wir erst einmal zum Stillstand gekommen.
Ob das jetzt Einkaufpreise sind oder ob es sich jetzt um den Griff ins fallende Messer handelt, wird notgedrungen erst in 1-2 Wochen beurteilbar sein, wenn nicht sensationell schnell eine Erholung eintritt.
Jedenfalls wäre es die Gelegenheit zu verbilligen. Vielleicht nach dem Wochenende

[dottore]

die rasche Kursverdreifachung muss wohl erst einmal verdaut werden. Immerhin zeichnet sich ein Niveu von 60 $-Cent ab.

[dottore]

Antwort auf Beitrag Nr.: 37.734.764 von dottore am 07.08.09 17:52:21

60 Cent?! neee fällt ins Bodenlose. Wann kann man da einsteigen ohne sich die Finger zu verbrennen? jetzt 48 Cent

[dottore]

Antwort auf Beitrag Nr.: 37.735.120 von dottore am 07.08.09 18:39:38

upps, hab ich mich verguckt? Doch bei 60 Cent?!!

[dottore]

und wieder rauf. Achterbahn! Schon mit 2000 Stück geht es wieder kräftig hoch

[KillingJoke]

Antwort auf Beitrag Nr.: 37.754.969 von dottore am 11.08.09 15:51:59

Hallo dottore,

machs doch mal konkreter.
Warum bist Du bei Icagen eingestiegen und was sind Deine Erwartungen in den Wert?

Gruss,
KJ


P.S.: Unter dem gewählten Threadtitel kann man ja kaum länger als 3 Monate diskutieren. Warum hast Du nicht geschrieben: "Icagen (ICGN) - Kommt das Buyout?" oder "Icagen's (ICGN) giftige Pillen" in Anlehnung an den Ende 2008 etablierten Shareholder Rights Plan?

[dottore]

Sep 1, 2009, 8:01 a.m. EST

Icagen Reports Top Line Results of Phase IIa Study of Senicapoc in Allergic Asthma

Kurs zieht um 30% an

[KillingJoke]

Antwort auf Beitrag Nr.: 37.895.992 von dottore am 01.09.09 18:19:21

Die Ergebnisse der klinischen Phase-II Asthma Studien von Senicapoc sind als sehr positiv zu bewerten.
Senicapoc war das Hauptmedikament von Icagen gegen Sichelzellenanämie, erfüllte aber die Wirksamkeitsnachweise der Phase-III-Studien nicht.
Der Kurs fiel in 2006 von 8 auf 1 USD und Icagen konzentrierte sich auf andere Betätigungsfelder.
Im August 2007 startete die Kooperation mit Pfizer zur Entdeckung und Entwicklung neuartiger Arzneimittel zur Schmerztherapie.

In den Phase-III Studien gegen Sichelzellenanämie wurde jedoch bereits nachgewiesen, dass Senicapoc ein günstiges Sicherheits- und Verträglichkeitsprofil besitzt.
Mit der gestern erfolgten, erfolgreichen Zwischenmeldung zur Wirksamkeit bei Asthma besitzt Icagen Potential für die mögliche Zulassung in einem viel größeren therapeutischen Markt!

Der aktuelle Kurs bei 1,43 USD ist aber auch schon sehr gut, immerhin standen wir im gesamten ersten Halbjahr bei kaum mehr als 0,40 USD. Ich könnte mir aktuell erst mal Gewinnmitnahmen vorstellen.


Gruss
KJ

[dottore]

gestern in USA Schlußkurs auf dem Höchststand. Das ist der zweite Ausbruch nach oben. Der wird nachhaltiger und ist die letzte Chance günstig einzusteigen.
Das Ask von 86 Cent h<t aber schon einen geringen Anstieg vorweggenommen.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 37.960.350 von dottore am 11.09.09 10:04:21

sieht aus als wenn mann sie auch noch einmal für eine $ bekommt

[Peederwoogn2]

Icagen Announces Extension of Pfizer Collaboration
Icagen Announces Extension of Pfizer Collaboration
Sep. 21, 2009 (GlobeNewswire) --
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced a one year extension to a prior worldwide collaboration and licensing agreement with Pfizer aimed at discovering, developing and commercializing compounds that modify three specific sodium ion channels as new potential treatments for pain and related disorders.

For the past two years, Icagen and Pfizer have partnered to identify compounds that target three ion channels in a global research and development collaboration. The companies have also formed a joint research committee (JRC) to monitor and oversee the collaboration.

The ion channel targets included in the collaboration are sodium channels, which are important in the generation of electrical signals in nerve fibers that mediate the initiation, transmission and sensation of pain. By selectively targeting these sodium channels, the companies seek to develop effective treatments for serious pain disorders with few side effects.

During the extension period, Pfizer will continue to fund all aspects of the collaboration including research efforts at both companies. Pfizer also will continue to have exclusive worldwide rights to commercialize products resulting from the collaboration. Under the terms of the extended agreement, Pfizer will provide approximately $5.0 million in committed funding to Icagen over the next year of the collaboration through September 30, 2010. Additionally, Icagen remains eligible to receive approximately $359 million in research, development, regulatory and commercialization milestones for each product. Icagen is also eligible to receive tiered royalties, against which the commercialization milestones are creditable, based upon product sales.

"We are very pleased to announce this extension of our previous collaboration with Pfizer," noted P. Kay Wagoner, Ph.D., President and CEO of Icagen. "We have had a great partnership thus far and remain confident that the combined abilities of our two companies will help identify novel drug candidates directed at one or more of these important sodium channel targets for the treatment of pain and related disorders."

Gillian Burgess, Ph.D., Chief Scientific Officer of Pfizer's Pain Research Unit and member of the Icagen-Pfizer JRC, continued, "We have made substantial progress over the first two years of our collaboration and look forward to working with Icagen in the upcoming year in seeking to identify drug candidates from these targeted programs."

[dottore]

soeben gefunden

9/24/2009 8:16:25 AM *
Icagen Initiates Proof-of-concept Study Of ICA-105665 In Patients With Photosensitive Epilepsy (ICGN)

[dottore]

Antwort auf Beitrag Nr.: 38.048.662 von dottore am 24.09.09 15:00:24

und noch etwas

RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. today announced the initiation of a proof-of-mechanism study of ICA-105665 for the treatment of pain. ICA-105665 is a novel, orally available opener of subtypes of KCNQ channels, which have been validated by both genetic and physiologic evidence as playing an important role in certain conditions characterized by abnormal neuroexcitability, such as seizures, and potentially also chronic pain disorders.

This randomized, double-blind, placebo-controlled study will employ a cross-over design in order to assess the ability of ICA-105665 to decrease the sensation of pain in response to the injection of a small amount of capsaicin under the skin and to a simulated sunburn. Approximately twenty-four healthy volunteers are expected to be enrolled in the study, which will be conducted at a single clinical research site in the United Kingdom. Initial results are expected during the first half of 2010.

"We are pleased to announce the initiation of this proof-of-mechanism study of ICA-105665 in pain," noted Seth V. Hetherington, M.D., SVP of Clinical Development and Regulatory Affairs of Icagen. "ICA-105665 has demonstrated activity in several preclinical pain models. Additionally, KCNQ channels are known to play an important role in regulating the resting membrane potential of neurons involved in pain pathways, and thereby have the potential to influence the transmission of pain signals. We look forward to conducting this focused, cost-effective study to begin to understand the potential utility of ICA-105665 in the treatment of pain."

[Flocke7815]

Scheint interessant zu sein, für einen kurzen Zock...
Kurz warten bis unter 20€cent und dann 1 Monat warten und schon verdoppelt sich der Einsatz....

Noch ein wenig warten dann schlage ich zu...

[KillingJoke]

Antwort auf Beitrag Nr.: 39.046.057 von Flocke7815 am 02.03.10 23:38:07

Icagen Reports Positive Results for ICA-105665 in Patients With Photosensitive Epilepsy

http://ir.icagen.com/phoenix.zhtml?c=178443&p=RssLanding&cat…

Auszug:
"Mar 15, 2010 - Icagen, Inc. (Nasdaq:ICGN) today reported positive results in its Phase IIa epilepsy study of ICA-105665, the Company's novel orally available small molecule KCNQ potassium channel agonist. "

[Stammzelle01]

Fri Jun 24, 2011 6:22pm EDT
(Provides details about talks between drugmakers)

(Reuters) - Pfizer Inc (PFE.N) said on Friday it is considering a "strategic transaction" with Icagen Inc (ICGN.O), a tiny biotechnology company in which Pfizer holds a 14.2 cent stake.

Icagen shares jumped $1.61, or 67 percent, to $4.01 in after hours trading, following the announcement.

"Icagen representatives and Pfizer employees have engaged in preliminary discussions regarding a potential strategic transaction," Pfizer said in a regulatory filing.

The world's largest drugmaker, which owns almost 1.1 million common shares of Icagen, said the company had given it access to due diligence materials.

Pfizer forged in 2007 a research and licensing deal with Icagen, relating to medicines to treat pain and related disorders. The biotech is based in Research Triangle Park, North Carolina.

Pfizer said ongoing talks with Icagen could lead to an extension or amendment of their longstanding agreement. The drugmaker said a strategic transaction could influence or change control of Icagen "by means of a stock or asset acquisition or merger."

Icagen, in a release late on Friday, acknowledged it is engaged in preliminary discussions with Pfizer regarding a potential strategic transaction. But it noted there can be no assurance any agreement will be reached. (Reporting by Ransdell Pierson; editing by Andre Grenon)

http://www.reuters.com/article/2011/06/24/...ealthcareNews&r…


Leute in den USA spricht man von eventuellen 24-48 Dollar als Kursziel!!!!!!!!

[Stammzelle01]

Icagen Pops on Pfizer Buyout Buzz: Pain and More on Table


Shares of Icagen Inc. popped more than 150 percent in early trading Monday on news that the biotech is engaged in preliminary buyout discussions with long-time partner Pfizer Inc. (PFE)

Late Friday, Pfizer filed a Schedule 13-D revealing that, as part of its ongoing evaluation of its deal with Icagen, the big pharma is "evaluating the possibility of entering into a strategic transaction with Icagen . . . by means of a stock or asset acquisition or merger." A confidentiality agreement has been signed and due diligence is under way.

Icagen subsequently issued its own press release acknowledging that it is "currently engaged in preliminary discussions with Pfizer" but that no definitive agreement has been reached.

Despite the cautionary language, Icagen investors were stoked. Shares of the Research Triangle Park, N.C.-based biotech (NASDAQ:ICGN) popped to a new 52-week high on Monday and closed at $6.33, a gain of 163.8 percent, or $3.93, for the day.

Pfizer and Icagen signed a billion-dollar deal in 2007 for rights to Icagen's sodium ion channel modifiers in pain indications. The deal covered compounds targeting three specific ion channels, and Icagen stands to get up to $359 million in research, development, regulatory and commercialization milestones for each product, plus royalties. (See BioWorld Today, Aug. 15, 2007.)

The deal was extended in 2009 and again in 2010. Pfizer bought stock in Icagen as part of the deal and currently owns 1 .07 million shares about 14 percent of the biotech.

Late last year, Pfizer and Icagen said they had picked a compound targeting the sodium ion channel Nav1 .7 as their lead candidate for clinical studies. That brought $1 million to Icagen and sent the biotech's stock up 78.7 percent. (See BioWorld Today, Dec. 1 , 2010.)

Icagen needed the good news: The biotech had suffered several setbacks over the past few years including Johnson & Johnson bailing on a partnership after the failure of senicapoc in a Phase III sickle cell trial, Bristol-Myers Squibb Co. dropping work on an atrial fibrillation compound, a Phase II failure of senicapoc in asthma, and a clinical hold on epilepsy compound ICA-105665.

Pfizer needs some good news, too, particularly in its pain pipeline. Last year, the big pharma suspended a massive clinical program for anti-NGF antibody tanezumab in osteoarthritis pain. Pfizer was running some 19 clinical trials in upward of 9,000 patients at the time of the suspension. Last year's acquisition of King Pharmaceuticals Inc. went a long way toward filling the pain pipeline gap, but last week's receipt of another complete response letter for Remoxy (extended-release oxycodone) was another tough blow. (See BioWorld Today, June 25, 2010, Oct. 13, 2010, and June 27, 2011 .)

If Pfizer does acquire Icagen, it would get more than the pain program on which the two companies already collaborate.

Icagen recently made steps toward getting ICA-105665 back on track in epilepsy. The FDA removed the clinical hold on the drug, which previously met its primary endpoint in a Phase IIa study measuring its ability to reduce the photic-induced epileptiform EEG response in patients with epilepsy. (See BioWorld Today, March 17, 2010.)

More good news: ICA-105665 is a KCNQ potassium channel agonist, and earlier this month the FDA approved Valeant Pharmaceuticals International Inc. and partner GlaxoSmithKline plc's epilepsy drug Potiga (ezogabine), which also acts at KCNQ ion channels and may help validate the approach. (See BioWorld Today, June 14, 2011.)

Earlier in its pipeline, Icagen is in preclinical development with compounds targeting ion channels associated with inflammatory disease.

(c) 2011 Thomson BioWorld, All Rights Reserved.


http://seekingalpha.com/news-article/1340991-icagen-pops-on-…

[Stammzelle01]

BY ALAN M. WOLF - STAFF WRITER
There's nothing like a takeover rumor to get investors excited.

Shares of Icagen, a small Durham drug-development company that had fallen far out of favor on Wall Street, more than doubled Monday.

The spark for the rally, which was the biggest one-day jump since the stock began trading publicly in 2005, was news that Icagen might be bought by larger partner Pfizer.

Late Friday, after the close of regular stock-market trading, Pfizer disclosed that it's in confidential discussions about a "strategic transaction" with Icagen. Pfizer, the world's largest drugmaker, first formed a partnership with Icagen in 2007 to develop new pain medicines.

Icagen could be worth $50 million to $100 million in a takeover, McNicoll, Lewis & Vlak analyst Christopher James told Bloomberg News. That would make Icagen's shares worth up to $13 each.

Icagen's shares rose $3.93 Monday to close at $6.33. That's the highest level in more than a year.

Pfizer owns more than 1 million Icagen shares, making it the company's largest investor.

Icagen officials, in a statement late Friday, confirmed the talks with Pfizer but said they wouldn't have further comment until there is a "definitive agreement or the current discussions have terminated."

Chief Financial Officer Richard Katz declined to comment Monday.

Founded in 1992, Icagen is one of several drug-development companies based on university research that dot the Triangle. And like many others, Icagen is incurring big losses.

Icagen shares began trading in 2005 at the equivalent of $64 each. But investors soured on the company's prospects the following year as it stumbled in its efforts to get an experimental drug past regulators.

In addition to the research on pain drugs that Icagen is conducting under its Pfizer partnership, the company is developing medicine to treat epilepsy. Icagen employs about 40 people and supports much of its business with fees from Pfizer tied to the experimental pain drugs.

Icagen and Pfizer recently started a second early-stage study of an experimental pain treatment.


http://www.newsobserver.com/2011/06/28/1306163/rumor-propels…